New resource highlights the critical role of lifestyle interventions in maximising weight loss success and addressing limitations of GLP-1 therapies
Ideal Protein, a leader in scientifically validated weight management solutions, announced the release of its groundbreaking whitepaper, “Maximizing the Promise of GLP-1 Medications” This comprehensive document explores how integrating GLP-1 receptor agonists—such as Ozempic, Wegovy, and Zepbound—with structured nutrition, coaching, and behavioural support can bridge the growing care gap in obesity treatment and drive sustainable health outcomes.
GLP-1 medications have revolutionised obesity treatment, yet challenges like affordability, side effects, muscle loss, and weight regain persist. According to the whitepaper, 30 per cent of patients discontinue GLP-1s within 30 days, while studies show 40-60 per cent of total weight lost on these medications may come from muscle mass, exacerbating long-term health risks. Ideal Protein’s protocol addresses these issues through a protein-forward dietary approach, personalised coaching, and micronutrient support, proven to preserve 95-98 per cent of lean body mass during weight loss.
“As we move into the era of improved weight loss medications such as GLP-1s, it is important to remember that the treatment of obesity and nutritional metabolic disorders requires a multipronged approach,” said Dr Douglas Rothrock, MD, FABIM, FACC, FABOM, Chief Scientific Advisor at Ideal Protein. “Nutritional training, behaviour modification, and physical activity are still key to maintaining a proper weight and metabolic reset. Ideal Protein is in the perfect position to be the partner with weight loss medications and GLP-1s to promote a broad and significant metabolic reset with weight loss.”
